Attention Deficit Hyperactivity Disorder: Selection of the Optimum Duration of Medical Treatment

Zavadenko, N. N.; Suvorinova, N. Yu.

doi:10.1007/s11055-013-9738-8

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eligible patients in the main study were either initiating or switching treatment for ADHD and only patients initiating monotherapy with a stimulant (methylphenidate), nootropic or atomoxetine for the treatment of ADHD could be enrolled in the study. Stimulant medications are not approved for ADHD treatment in the Russian Federation and thus, nootropic medications, such as piracetam, are used as a result of their actions as cognitive enhancers . Since nootropic use is unique to the Russian Federation, it was not included in the analysis; the focus was on methylphenidate and atomoxetine.…”

Section: Methodsmentioning

confidence: 99%

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

Treuer¹,

Feng

Desaiah

et al. 2014

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

Treuer¹,

Feng

Desaiah

et al. 2014

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…The therapeutic effect was apparent in terms of tranquilizing, activating, and euhypnotic actions; all children showed increased physical and mental work capacity, improvements in memory, decreases in irritability, anxiety, restlessness, and in some cases concomitant enuresis, tics, stuttering, and sleep disturbances. We have also studied [11] the actions of phenibut in investigations of 20 children with ADHD (17 boys and three girls aged 7-10 years). Phenibut was prescribed as 250-mg tablets at a daily dose of 12.5 mg/kg (250-375 mg/day) p.o.…”

Section: Resultsmentioning

confidence: 99%

Results of Pharmacotherapy of Attention Deficit Hyperactivity Disorder: Assessment Using Neuropsychological Methods

Zavadenko

Suvorinova

2016

Neurosci Behav Physi

Self Cite

View full text Add to dashboard Cite

Attention defi cit hyperactivity disorder (ADHD) is one of the most widespread disorders in children and adolescents. It occurs in about 5% of children and is more common in boys than girls, with a ratio of 2:1 [1]. ADHD is characterized by a protracted course, but it susceptible to treatment with contemporary agents.Diagnoses are based on international clinical criteria, including lists of the most typical and clearly apparent symptoms. However, the identifi cation of objective signs of ADHD in children involves some diffi culties because of the fact that the patient's status can change in various situations and at different times, as well as in relation to types of activity and the child's attitudes to them. This presents specialists with the need to design investigations such that the child's behavioral characteristics are assessed not only during medical examination, but also at home, at school, and in other non-medical contexts. It is therefore important to obtain relevant reports from parents, carers, and teachers using surveys and specially designed questionnaires. It should be emphasized that assessment of ADHD symptoms using surveys is only the initial stage of diagnosis, which must be followed by detailed psychological investigation.During the psychological investigation of children with ADHD, assessment methods address not only general mental development, but also individual higher mental functions, particularly attention and memory. It is important to discriminate the various types and properties of attention. Sustained attention is the ability to maintain the required response during prolonged and repeated activity, so this property of attention is often termed continuity or stability; selective attention has two types, focused and distributed; focused attention is linked with properties of attention such as targeting, and is the ability to respond in a defi ned way to specifi c stimuli; distributed attention is the ability to run several cognitive operations during the performance of a given task. A further property of attention is its ability to undergo switching, which refl ects the fl exibility of cognitive processes.As regards neuroanatomy, i.e., the structural basis for attention, this is considered [2] to consist of three systems: the vigilance system, which includes the fi elds of the frontal and parietal cortex, mainly of the right hemisphere, the oriStudy aim. To investigate the dynamics of measures of behavior, attention, and memory during treatment with Noofen (250-mg capsules) in children with attention defi cit hyperactivity disorder (ADHD). Materials and methods. A total of 50 patients taking part in an open study were divided into two groups of 25 patients: patients of group 1 received Noofen while patients of group 2 (controls) received only low doses of multivitamins. Treatment lasted one month. Noofen was given at doses of 15-20 mg/kg (500-750 mg) per day using 250-mg capsules, as two or three doses. Results and conclusions. Neuropsychological test results at the end of one month o...

show abstract

“…Russia as well as some Asian, Middle Eastern, and Northern African countries, amongst others, are less studied in terms of typical patterns of ADHD pharmacological treatment. In Russia, where stimulant medications do not have marketing approval, ADHD is treated with a range of drugs; mainly nootropic agents, such as piracetam, are used due to their actions as cognitive enhancers [ 12 , 13 ]. However, in most other parts of the world, especially in non-Western countries, stimulant medications are likely to be the preferred form of drug treatment for ADHD [ 11 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Altin¹,

Elshafei²,

Yu³

et al. 2013

DIC

View full text Add to dashboard Cite

Objective:Functional outcomes were measured over a 12-month period in children and adolescents with attention deficit hyperactivity disorder (ADHD) after they received monotherapy.Design:Prospective, observational, noninterventional study.Setting:Conducted in six non-Western countries.Participants:Outpatients 6 to 17 years of age with a verified diagnosis of ADHD in accordance with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), together with their physicians, decided to initiate or switch treatment for ADHD. Patients were prescribed pharmacological monotherapy: methylphenidate (n=221), nootropic agents (n=91), or atomoxetine (n=234).Measurements:Patients were followed for changes in their functional status and quality of life, which were assessed with the Child Health and Illness Profile–Child Edition (CHIP-CE) Achievement domain.Results:At the end of the study, a mean improvement on the CHIP-CE Achievement domain score was observed for all countries and therapies except in Taiwan, where patients received atomoxetine, and in Lebanon, where patients received methylphenidate. No patient experienced a serious adverse event during the study. Four patients discontinued due to a treatment-emergent adverse event.Conclusion:After 12 months of treatment, clinical and functional outcomes were improved in children and adolescents from non-Western countries who initiated and remained on their prescribed pharmacological monotherapy.

show abstract

Attention Deficit Hyperactivity Disorder: Selection of the Optimum Duration of Medical Treatment

Cited by 4 publications

References 1 publication

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates

Results of Pharmacotherapy of Attention Deficit Hyperactivity Disorder: Assessment Using Neuropsychological Methods

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Contact Info

Product

Resources

About